Keywords: pfizer, lipitor, suffer, most, zocor, patent, expiry
Pfizer's Lipitor "will suffer most" from Zocor's patent expiry; report
Article | 29 May 2006
Primary care physicians and cardiologists in the USA expect to substantially decrease their prescribing of Pfizer's blockbuster cholesterol-lowerer Lipitor (atorvastatin) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
